Roche has doubled its anti-tau pipeline for Alzheimer’s disease, paying $120m upfront for rights to UCB’s UCB0107 candidate that will serve as a back-up to its own semorinemab in phase 2 ...

The pipeline news was announced as Roche reported a 6% fall in its first-quarter pharma revenues to just under CHF 11 billion ($12 billion), which it said was equivalent to a 2% increase if ...